The Oncology Institute, Inc. · NASDAQ:TOI
The Oncology Institute — Starling Oncology — Investor Presentation (November 2026)
29 slides from The Oncology Institute's investor presentation, Nov 12, 2026
Slide 1: Forward-looking statements disclaimer
Some of the information in this presentation is not historical in nature and may constitute forward - looking statements, which ar e made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward - looking
Slide 2: Forward-looking statements disclaimer
Some of the information in this presentation is not historical in nature and may constitute forward - looking statements, which ar e made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward - looking
Slide 3: Investment Highlights
3 Starling Oncology | Investor Presentation 5 4 3 2 1 A leading national oncology - focused VBC Platform Large TAM, with long - term growth driven by secular trends Balanced model with at - risk VBC and FFS ancillary services Multiple levers for growth across a diversified business Proven leadership
Slide 4: High-Quality Care Delivery & Benefits Management Platform
4 Starling Oncology | Investor Presentation High - Quality Care Delivery & Benefits Management Platform Benefits Management Platform Care Delivery Delegated provider network management Utilization and case management Drug formulary Claims adjudication Patient call center Community oncologists Nursin
Slide 5: Starling Oncology At A Glance
Starling Oncology At A Glance 5 Starling Oncology | Investor Presentation Note: 2026E reflects the midpoint of FY2026 revenue guidance of $650 – 660M, as provided in the Company’s 3Q’26 earnings release ( November 5, 2026). 1. Reflects all individually contracted plans and geographies OPERATIONAL FO
Slide 6: Recent Announcements
Recent Announcements 6 Starling Oncology | Investor Presentation Jul 7, 2026 Aug 3, 2026 4Q26 Aug 17, 2026 Repaid the $86M Deerfield note through a strategic refinancing with OrbiMed , strengthening the balance sheet while expanding revolver capacity to $25M Relaunched as Starling Oncology and began
Slide 7: Oncology Care Costs Are Rising Rapidly
(1) American Cancer Society. (2) National Cancer Institute. (3) Wall street research. (4) IQVIA Institute for Human Data Scie nce . Oncology Care Costs Are Rising Rapidly 7 Starling Oncology | Investor Presentation 2.1M+ New U.S. cancer diagnoses in 2026 (+25% vs. 2016) (1) $246B Total U.S. cancer c
Slide 8: Fee-for-Service Oncology Misaligns Incentives
(1) IQVIA. (2) AmerisourceBergen / Oncology Supply practice benchmarking. Fee - for - Service Oncology Misaligns Incentives 8 Starling Oncology | Investor Presentation U.S. ONCOLOGY SPEND 1 $99B → $180B U.S. oncology drug spending nearly doubles by 2028 (1) 2 ~$412K Median cost of a new oncology dru
Slide 9: Starling Oncology Solutions and Scale
Starling Oncology Solutions and Scale 9 Starling Oncology | Investor Presentation % OF REVENUE (1) Capitation Fixed per - member - per - month payments from payors to manage a population's oncology care. Fee - for - Service Billing insurance and copay for E&M visits, infusions, drug resale, and radi
Slide 10: National Footprint with Significant Upside
National Footprint with Significant Upside Non - CA markets are the growth engine — lives up 272% and revenue up 44% since 2024 Lives by State (Lives in thousands) Revenue by State ($ in millions) 1,813 1,765 67 249 1,880 2,015 2024 2025 $315 $391 $78 $112 $393 $503 2024 2025 CA Non - CA CA Non - CA
Slide 11: Full-Spectrum Capitated Offering
Starling Oncology’s Full - Spectrum Capitated Offering 11 Starling Oncology | Investor Presentation FUTURE OF STARLING ONCOLOGY GROWTH Narrow Network Capitation Starling Oncology contracts with providers that are globally capitated with a Knox - Keene license to serve as the exclusive oncology provi
Slide 12: Narrow and Delegated Patient Pathways
Step 1 Step 2 Step 3 Starling Oncology contracts with Payor to manage oncology care via: Oncology patients seen for capitated outpatient medical oncology services in Starling Oncology or network clinic STLN captures additional clinical revenue from services not included in capitation for outpatient
Slide 13: Proven Ability to Maintain Stable MLR at Scale
Proven Ability to Maintain Stable MLR at Scale Launched Delegated contract model and began on - boarding those patients 4Q24 1Q25 2Q25 3Q25 4Q25 1Q26 2Q26 3Q26 Consistent MLR Performance Despite Elevated Industry Utilization Cap Revenue ($M) (1) MLR (1)(2) MLR expected in 85 – 90% range over next 12
Slide 14: Delegated Capitation: Health Plan Solution
Delegated Contract Ramp Revenue Gross Margin 1 2 3 4 5 6 7 8 9 10 11 12 Months MONTHS 1 – 4 Transition of Care Period MONTHS 5 – 8 VBC Adoption MONTHS 9 – 12 Mature State Clinics Outside CA: Owned vs. Networked 23 24 25 67 222 2024 2025 2026 Delegated Members Growth & Diversification 4Q24 1Q25 2Q25
Slide 15: Specialty Pharmacy Overview
Revenue & Gross Margin $100M $180M $269M $29M $31M $46M 2023 2024 2025 Multi - Year Growth in Script Volume 8K 11K 20K 33K ~60K+ 2022 2023 2024 2025 2026E Scripts per 1K Visits & Clinic Visits 51K 51K 50K 52K 56K 51K 54K 56K 60K 3Q24 4Q24 1Q25 2Q25 3Q25 4Q25 1Q26 2Q26 3Q26 102 115 122 156 184 208 22
Slide 16: The Starling Oncology Care Model
16 Starling Oncology | Investor Presentation The Starling Oncology Care Model Care Navigation Program with Proven Outcomes Accessible Community - based locations Comprehensive Hospital Coverage Integrated Medical and Radiation Oncology Well - recognized Physicians Internal Second - Opinion Network O
Slide 17: Starling Oncology Nexus
Starling Oncology Nexus (1) A proprietary industry - leading UM platform promoting provider engagement Starling Oncology | Investor Presentation (1) - Patent Pending 17 A unified platform for value - based care Starling’s proprietary platform connects utilization management, clinical pathways, real
Slide 18: Starling Oncology Nexus Screenshots
Starling Oncology Nexus Screenshots Starling Oncology | Investor Presentation 18
Slide 19: Nexus Performance KPIs – Early Wins
Nexus Performance KPIs – Early Wins Starling Oncology | Investor Presentation (1) Based on 3 months of 2026 data 19 >80% Minimum number of cases submitted weekly
Slide 20: What Sets Starling Apart in a Competitive Landscape
What Sets Starling Apart in a Competitive Landscape 20 Starling Oncology | Investor Presentation Care Delivery Model Provide Clinical Care Utilization Management Incentivized to Keep Drug Costs Low Purchasing Drugs at Scale Care Navigation Model Utilization Management Only Subsidiary of a Distributo
Slide 21: Leadership Team
= Daniel Virnich, MD Chief Executive Officer • Joined STLN in 2020 as COO, CEO since 2023 • 20+ years of executive leadership and value - based care operations experience • Previously, served as President of DaVita Medical Group, Florida and Senior VP of Operations for Healthcare Partners in Souther
Slide 22: Financial Overview
Financial Overview 22 Starling Oncology | Investor Presentation
Slide 23: Financial Highlights
23 Starling Oncology | Investor Presentation Financial Highlights 1 Diversified Revenue Base Revenue spans capitation, fee - for - service, specialty pharmacy, and clinical solutions, reducing reliance on any single payer model 2 Recurring, Visible Revenue Multi - year capitation contracts and recur
Slide 24: Consistent Revenue Growth
Consistent Revenue Growth 24 Starling Oncology | Investor Presentation Patient Lives (M) Adjusted EBITDA ($M) Revenue ($M) ($35.7) 2024 ($12.4) ($25.8) 2023 2025 $324M 2023 $393M 2024 $503M 2025 Capitated Revenue FFS Revenue Specialty Pharmacy Clinical Trials & Other $655M 2026E $3M - $5M 2026E Note
Slide 25: 3Q26 Quarterly Results
3Q26 Quarterly Results 25 Starling Oncology | Investor Presentation Notes: (1) Adjusted EBITDA is a non - GAAP measure. A reconciliation to the nearest GAAP measure is available upon request. Revenue Adjusted EBITDA (1) Patient Lives 3Q26 Operational Highlights ($ in millions) ($ in millions) (mil
Slide 26: Pharma Margin Bridge
Pharma Margin Bridge Starling Oncology | Investor Presentation 26 Pharma Margin Drivers 18 – 19% +2 – 3% 21 – 24% Including Incremental Margin Opportunity 18 – 21% Baseline Margin Scaled Procurement Activities Opportunistic Pricing Current Margin Long - term Margin +0 – 2% Incremental Margin Opportu
Slide 27: Path to Breakeven and Profitability
Path to Breakeven and Profitability Levers 27 Starling Oncology | Investor Presentation SG&A historically declining as a Percentage of Revenue, Gross Margins Trending Higher Margin Levers Gross Margin • Leverage existing clinical labor • Drive Specialty Pharmacy, Clinical Research, and behavioral at
Slide 28: Longer Term Guidance
Longer Term Guidance 28 Starling Oncology | Investor Presentation FY2025 FY2026 2028 TARGETS REVENUE $502.7M GROSS PROFIT $76.4M ADJUSTED EBITDA $(12.4)M FREE CASH FLOW $(23.9)M REVENUE $650 – $6 6 0M + 30 % mid. GROSS PROFIT $10 7 – $110M +4 0 % mid. ADJUSTED EBITDA $ 4 – $ 6 M TURNS + FREE CASH FL
Slide 29: Investment Highlights
29 Starling Oncology | Investor Presentation 5 4 3 2 1 A leading national oncology - focused VBC Platform Large TAM, with long - term growth driven by secular trends Balanced model with at - risk VBC and FFS ancillary services Multiple levers for growth across a diversified business Proven leadershi
Starling Oncology — Investor Presentation (November 2026) on 6ix